Programmed cell death protein (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhibition checkpoint blockade leads to various cutaneous adverse reactions, including bullous pemphigoid and lichen‐planus‐like reactions. However, lichen planus pemphigoides (LPP),… Click to show full abstract
Programmed cell death protein (PD‐1) and programmed death‐ligand 1 (PD‐L1) inhibition checkpoint blockade leads to various cutaneous adverse reactions, including bullous pemphigoid and lichen‐planus‐like reactions. However, lichen planus pemphigoides (LPP), manifesting histopathologic features of both lichen planus and bullous pemphigoid, has more rarely been associated with immunotherapy.
               
Click one of the above tabs to view related content.